Kazia Therapeutics Limited ADR (KZIA) concluded trading on Thursday at a closing price of $1.90, with 103.73 million shares of worth about $197.09 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -49.56% during that period and on January 30, 2025 the price saw a gain of about 37.68%. Currently the company’s common shares owned by public are about 3.33M shares, out of which, 2.91M shares are available for trading.
Stock saw a price change of 29.25% in past 5 days and over the past one month there was a price change of -38.11%. Year-to-date (YTD), KZIA shares are showing a performance of 7.34% which decreased to -43.87% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.32 but also hit the highest price of $15.80 during that period. The average intraday trading volume for Kazia Therapeutics Limited ADR shares is 100.47K. The stock is currently trading 19.50% above its 20-day simple moving average (SMA20), while that difference is down -39.86% for SMA50 and it goes to -48.06% lower than SMA200.
Kazia Therapeutics Limited ADR (NASDAQ: KZIA) currently have 3.33M outstanding shares and institutions hold larger chunk of about 6.58% of that.
The stock has a current market capitalization of $6.33M and its 3Y-monthly beta is at 2.10. It has posted earnings per share of -$6.66 in the same period. It has Quick Ratio of 0.24. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KZIA, volatility over the week remained 26.19% while standing at 16.48% over the month.
Analysts are in expectations that Kazia Therapeutics Limited ADR (KZIA) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Maxim Group on October 14, 2021 offering a Buy rating for the stock and assigned a target price of $18 to it. Coverage by H.C. Wainwright stated Kazia Therapeutics Limited ADR (KZIA) stock as a Buy in their note to investors on January 05, 2021, suggesting a price target of $17 for the stock.
